Nasdaq

Outlook Therapeutics Discusses NORSE EIGHT Clinical Trial Results and Future Plans for ONS-5010

Outlook Therapeutics, Inc. has announced the participation of Dr. Jennifer Kissner, Senior Vice President of Clinical Development, in a Virtual Investor segment discussing the 12-week safety and ...
Seeking Alpha

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the ...
Seeking Alpha

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the ...
manilatimes

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
manilatimes

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...